At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
AZD2624 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD2624 in Adult Schizophrenia Patients
In Brief
A Phase 2 clinical trial evaluating AZD2624, Olanzapine, and 1 other intervention for Schizophrenia. Completed, enrolled 106 participants across 1 site.
Detailed Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedMay 2008
Primary CompletionMar 2009
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartMay 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.1 years ago
Interventions
AZD2624drug
Oral Suspension
Olanzapinedrug
PO BID
Placebodrug